We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA TO CONSOLIDATE AGENCY DRUG REVIEW CENTERS
FDA TO CONSOLIDATE AGENCY DRUG REVIEW CENTERS
April 7, 2004
Rather than curtailing services, the FDA plans to consolidate the agency’s 16 existing drug review centers into just three centers at the White Oak campus in Maryland, which should increase productivity and boost performance, according to an FDA spokesperson.